The drug seemed to make less of the bad cholesterol particle by turning fewer big particles into smaller ones, but this effect wasn’t strong enough to be sure it wasn’t just chance.
Scientific Claim
In miniature pigs treated with atorvastatin for 21 days, the reduction in LDL apolipoprotein B production is primarily attributed to a 34% decrease in the conversion of VLDL apoB to LDL apoB, although this change was not statistically significant (P=.114).
Original Statement
“The reduction in LDL apoB PR was primarily due to a 34% decrease in conversion of VLDL apoB to LDL apoB; however, this reduction was not statistically significant (P=.114).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract correctly reports the trend and its non-significance. No causal language is used, and the phrasing matches the data.
More Accurate Statement
“In miniature pigs treated with atorvastatin for 21 days, the reduction in LDL apolipoprotein B production was primarily attributed to a 34% decrease in the conversion of VLDL apoB to LDL apoB, although this change was not statistically significant (P=.114).”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bIn EvidenceThat atorvastatin causally reduces the conversion rate of VLDL apoB to LDL apoB in pigs.
That atorvastatin causally reduces the conversion rate of VLDL apoB to LDL apoB in pigs.
What This Would Prove
That atorvastatin causally reduces the conversion rate of VLDL apoB to LDL apoB in pigs.
Ideal Study Design
A double-blind, placebo-controlled RCT in 30+ miniature pigs, randomized to atorvastatin (3 mg/kg/day) or placebo for 21 days, with VLDL-to-LDL apoB conversion rate measured using dual-isotope labeling (131I-VLDL and 125I-LDL) and multicompartmental modeling as the primary endpoint.
Limitation: Cannot determine if the effect is due to hepatic lipid availability or enzyme activity changes.
Animal Study (Non-RCT)Level 4In EvidenceWhether the trend in VLDL-to-LDL conversion is reproducible under identical conditions.
Whether the trend in VLDL-to-LDL conversion is reproducible under identical conditions.
What This Would Prove
Whether the trend in VLDL-to-LDL conversion is reproducible under identical conditions.
Ideal Study Design
A non-randomized study in 15 miniature pigs treated with 3 mg/kg/day atorvastatin for 21 days under identical dietary and kinetic measurement conditions as the original study.
Limitation: Cannot rule out confounding by time, diet, or individual variability.
Evidence from Studies
Supporting (1)
Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
The study gave pigs a cholesterol-lowering drug called atorvastatin and found that less LDL cholesterol was made mainly because less of the bigger fat particles (VLDL) turned into smaller ones (LDL)—even though that drop wasn’t big enough to be 100% certain, it’s still the main reason the scientists think it happened.